MannKind files Afresa, downplays inhaled aspect of its insulin:
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Almost a year and a half after Pfizer admitted commercial defeat for the first inhaled insulin, Exubera, last-drug-developer-standing MannKind has filed the NDA for its inhaled insulin Afresa. The March 16 announcement continues MannKind's practice of downplaying the inhaled aspects of its insulin, stating that "the feature that distinguishes Afresa from all other insulin products is not the route of administration - it is the pharmacokinetic profile." Although the other manufacturers working on inhaled insulins abandoned the projects, MannKind persevered, arguing that the efficacy offered by the quick action (peak insulin levels in 12-14 minutes, mimicking the release of mealtime insulin in healthy people) - not convenience - is the rationale for the product. The firm also recently announced its plan to buy the German plant that produced Pfizer's Exubera. Having both the regulatory filing accomplished and the manufacturing capability should give the biotech a leg up in partnering talks - which had been put on hold after a lung cancer signal was detected in Exubera post-market data (1"The Pink Sheet" DAILY, Nov. 10, 2008)
You may also be interested in...
MannKind Says Inhaled Insulin NDA On Track, Resumes Search For Partner
Afresa Phase III studies are complete, though FDA wants bioequivalence trial to support new inhaler device.
Biden Extends Helping Hand To Small US Manufacturers, Vendors With ‘Made In America’ EO
The president’s executive order aims to give smaller companies a leg up over foreign competitors, among other objectives.
Warning Letter Roundup & Recap – 26 January 2021
No device-related warning letters were released by the US FDA the week of 26 January.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: